Fluoropolymer Coatings Market Advances as High-Performance Surface Protection Gains Ground Across Demanding Industrial Applications

As per SNS Insider, the Fluoropolymer Coatings Market is projected to reach USD 4.80 Billion by 2035, growing at a 5.28% CAGR, while the U.S. market is expected to reach USD 2.12 billion, advancing at 5.82% CAGR, as demand rises for durable, corrosion-resistant surface protection.

As per SNS Insider, the Fluoropolymer Coatings Market is projected to reach USD 4.80 Billion by 2035, growing at a 5.28% CAGR, while the U.S. market is expected to reach USD 2.12 billion, advancing at 5.82% CAGR, as demand rises for durable, corrosion-resistant surface protection.

Host Digital Inc. Announces Closing of Common Stock Offering

NEW YORK, NY, Sept. 21, 2026 (GLOBE NEWSWIRE) — Host Digital Inc. (f/k/a Healthy Choice Wellness Corp.) (NYSE American: HOST) (the “Company” or “Host Digital”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of 2,187,500 shares of its Class A common stock, par value $0.001 (the “Common Stock”), at a public offering price of $8.00 per share.

LI BANG INTERNATIONAL CORPORATION INC. Announces Adjournment of Extraordinary General Meeting

JIANGYIN, China, Sept. 21, 2026 (GLOBE NEWSWIRE) — Li Bang International Corporation Inc. (“Li Bang International”) and its subsidiaries (collectively, the “Company,” “we,” “us,” “our company,” or “Li Bang”) (Nasdaq: LBGJ), a company engaged in designing, developing, producing, and selling stainless steel commercial kitchen equipment in China, today announced that its Extraordinary General Meeting of Shareholders (the “Meeting”) has been adjourned to September 22, 2026 at 9:30 a.m., Eastern Time, at the Company’s principal office, due to the absence of a quorum.

LI BANG INTERNATIONAL CORPORATION INC. Announces Adjournment of Extraordinary General Meeting

JIANGYIN, China, Sept. 21, 2026 (GLOBE NEWSWIRE) — Li Bang International Corporation Inc. (“Li Bang International”) and its subsidiaries (collectively, the “Company,” “we,” “us,” “our company,” or “Li Bang”) (Nasdaq: LBGJ), a company engaged in designing, developing, producing, and selling stainless steel commercial kitchen equipment in China, today announced that its Extraordinary General Meeting of Shareholders (the “Meeting”) has been adjourned to September 22, 2026 at 9:30 a.m., Eastern Time, at the Company’s principal office, due to the absence of a quorum.

Thomas P. Clement Professorship Established at Howard Community College, Anchoring a Growing Engineering Innovation Ecosystem

Howard Community College Professor and Department Head of Engineering Dr. Ghazanfer Bozai will serve as the inaugural holder for a five-year term beginning this fall.

Howard Community College Professor and Department Head of Engineering Dr. Ghazanfer Bozai will serve as the inaugural holder for a five-year term beginning this fall.

Sutter Health Names Christina Oh Executive Vice President and Chief Operating Officer

SAN FRANCISCO, Sept. 21, 2026 (GLOBE NEWSWIRE) — Sutter Health today announced that Christina Oh has been named executive vice president and chief operating officer. She will expand her operational leadership role at the not-for-profit, integrated health system as it continues to enhance access, strengthen performance and advance more coordinated and advanced clinical care close to home for patients and communities.

Psoriatic Arthritis Market Landscape: 6 Key Late-Stage Drugs Set to Drive Future Growth | DelveInsight

The launch of emerging therapies such as ILUMYA/ILUMETRI (tildrakizumab-asmn; Sun Pharma), Izokibep (Affibody Medical), ICOTYDE (icotrokinra; Johnson & Johnson), Zasocitinib (TAK-279; Takeda), Sonelokimab (MoonLake Immunotherapeutics), Vunakizumab (Suzhou Suncadia), SPY 072 (Spyre Therapeutics), PN-881 (Protagonist Therapeutics), and others is expected to significantly reshape the Psoriatic Arthritis (PsA) market by expanding treatment options and addressing unmet needs among patients with inadequate responses to existing therapies.

The launch of emerging therapies such as ILUMYA/ILUMETRI (tildrakizumab-asmn; Sun Pharma), Izokibep (Affibody Medical), ICOTYDE (icotrokinra; Johnson & Johnson), Zasocitinib (TAK-279; Takeda), Sonelokimab (MoonLake Immunotherapeutics), Vunakizumab (Suzhou Suncadia), SPY 072 (Spyre Therapeutics), PN-881 (Protagonist Therapeutics), and others is expected to significantly reshape the Psoriatic Arthritis (PsA) market by expanding treatment options and addressing unmet needs among patients with inadequate responses to existing therapies.

Amundi : Programme de rachat d’actions – Déclaration des transactions sur actions propres réalisées du 14 septembre au 18 septembre 2026

Paris, 21 septembre 2026 – (Article 5 du règlement (UE) n° 596/2014 sur les abus de marché et Article 3 (3) du règlement délégué (UE) 2016/1052 complétant le règlement (UE) n° 596/2014 par des normes techniques de réglementation concernant les conditions applicables aux programmes de rachat et aux mesures de stabilisation).